Publications
62
Citations
787
Est. group size
~1
Recurring co-author estimate
Active years
7
Publishing since 2020
Jay K. Mandula's research focuses on cancer immunology, particularly how immune cells called CD8 T cells (a type of white blood cell that can kill tumor cells) can be strengthened to fight cancer. Recent work centers on a receptor called GPR84, which senses certain fats and appears to influence how these T cells use energy and metabolism to attack tumors. This research fits within the broader fields of cancer immunotherapy and biomarker development.
Publication output was minimal before 2020 but has grown substantially since, with a sharp spike in 2024 and 2026, driven largely by a single major study and its associated supplementary materials.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Cancer Immunology Research · 2026
- Supplementary Figure 13 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Table 1 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 14 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 1 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 5 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 4 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 12 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 8 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 3 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 2 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Table 3 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 9 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 10 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Supplementary Figure 11 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
2026
- Immunity×3
- The Journal of Immunology×3
- Cancer Cell×2
- Regular and Young Investigator Award Abstracts×2
- Cancer Research×2
- Chunyu Xu
Medicine · Purdue University West Lafayette
- Evandro D. Bezerra
Medicine · The Ohio State University
- Utkarsh Acharya
Medicine · The Ohio State University
- Bihui Cao
Medicine · Indiana University
- Audrey M. Sigmund
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile